Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 8, 2019

View Archived Issues

Novel transgenerational mouse model of insulin resistance

Mycobiome linked to pancreatic cancer

Dual inhibition of TGF-beta and AXL as novel therapeutic approach in metastatic CRC

rSIFN-co demonstrates antitumor activity in phase I study in advanced solid tumors

Phase I results for DNA vaccine MVI-118 in patients with metastatic prostate cancer

C-75 improves survival of mice with sepsis through blocking TLR/MYD88 signaling in neutrophils

Enrollment underway in phase I/II study of CTNS-RD-04 stem cell gene therapy for cystinosis

First cohort subject dosed in phase I study of SCD inhibitor YTX-7739

NKTR-358 begins new phase Ib studies in psoriasis and atopic dermatitis

Inhaled AZD-8154 demonstrates superior pharmacokinetics over intravenous administration

Hawaii Biotech divulges compounds for anthrax

Biogen patents OGA inhibitors

H. Lee Moffitt Cancer Center and Research Institute presents YAP1/POU5F1 interaction inhibitors

Aerie Pharmaceuticals synthesizes new kinase inhibitors

Genentech patents TRPA1 antagonists

Dermavant initiates phase IIa study of cerdulatinib gel in vitiligo

Phase III extension study of VM-202 in diabetic peripheral neuropathy meets primary endpoint

BARDA contract supports Platelet BioGenesis' development of donor-independent platelets

Advaxis updates median overall survival data from phase I/II study of ADXS-PSA in metastatic CRPC

FDA approves Beovu for wet age-related macular degeneration

Evaluating gepotidacin in the treatment of uncomplicated urinary tract infections: a phase IIa study

Three win Nobel for hypoxia work

Bavarian Nordic begins first-in-human study of MVA-BN-WEV for equine encephalitis virus

ONL Therapeutics advances ONL-1204 into phase I study for retinal detachment

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 9, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...